Presentation is loading. Please wait.

Presentation is loading. Please wait.

Washington D.C., USA, 22-27 July 2012www.aids2012.org HCV genotype and HBV co-infection associate with HCV clearance in HIV- positive subjects Yuan Dong,

Published byRandell Davis Modified over 8 years ago

Similar presentations

Presentation on theme: "Washington D.C., USA, 22-27 July 2012www.aids2012.org HCV genotype and HBV co-infection associate with HCV clearance in HIV- positive subjects Yuan Dong,"— Presentation transcript:

1 Washington D.C., USA, 22-27 July 2012www.aids2012.org HCV genotype and HBV co-infection associate with HCV clearance in HIV- positive subjects Yuan Dong, Chao Qiu, Xueshan Xia, Jing Wang, Haiyan Zhang, Yongheng Wang, Xiaoyan Zhang, Jianqing Xu Shanghai Public Health Clinical Center and Institutes of Biomedical Sciences, Fudan University, Shanghai, China

2 Washington D.C., USA, 22-27 July 2012www.aids2012.org Chronic liver disease is increasingly contributing to morbidity and mortality among people with HIV, particularly HCV- related liver disease Dominique Salmon-Ceron,et al. Journal of Hepatology, 2009, 50: 736-745 E. Rosenthal, et al. Journal of Viral Hepatitis, 2007, 14: 184-188

3 Washington D.C., USA, 22-27 July 2012www.aids2012.org Jialun Zhou, et al, Journal of Gastroenterology and Hepatology, 2007, 22: 1510-1518 Greub G, et al. Lancet. 2000 Nov 25;356(9244):1800-5. HCV prevalence in people with HIV (TAHOD, TREAT Asia HIV Observational Database; &The Swiss HIV Cohort study)

4 Washington D.C., USA, 22-27 July 2012www.aids2012.org Background It remains unknown the associations of HCV clearance in HIV-positive Chinese IDUs. Less is known about whether and how HCV genotypes affect its clearance.

5 HIV-HCV co-infection prevalence among IDUs in China 0 Yunnan (46.3%) Myanmar Thailand Laos Vietnam Xinjiang (36.2%)

6 Washington D.C., USA, 22-27 July 2012www.aids2012.org Study Objectives To determine the prevalence of HCV infection, spontaneous clearance and genotype distribution among HIV-positive IDUs from Yunnan, a region with the highest HIV-HCV co-infection prevalence in China. To search for factors that may affect the clearance of HCV and whether HCV genotypes could exert different influences on those factors.

7 HIV-positive IDUs were recruited in Yunnan Province ( Dali CDC, Compulsory detoxification, Labor camp ) Interview Sociodemographic information, high-risk behaviors and history of HIV-infection and medication Blood collection CD4 T cell count (FACSAria flow cytometry; BD Bioscience), ALT,TB Anti-HCV Ab (ELISA; Kehua Company) HBsAb, HBsAg, HBeAg, HBeAb, HBcAb (ELISA; Wantai Company) HCV viral load (Realtime-PCR; PG Biotech Company) HCV genotyping (5’NCR/ NS5B/ E1–E2; ABI Prism 3100 genetic analyzer) Data analysis SPSS software (version 17.0)

8 Washington D.C., USA, 22-27 July 2012www.aids2012.org Recruitment of HIV/HCV co-infected patients 529 HIV infected patients 47 HCV uninfected patients 24 newly infected HCV patients 1 had invalid data 457 HCV infected patients 98 HCV cleared patients359 HCV chronic infected patients 31 HBV uninfected 43 resolved HBV 24 chronic HBV 144 HBV uninfected 187 resolved HBV 28 chronic HBV

9 Washington D.C., USA, 22-27 July 2012www.aids2012.org Demographic characteristics Serum HCV RNA CharacteristicTotalNegativePositive Number of cases457 (100)98(21.4)359 (78.6) Age, median (range)33.00 (18-47)34.00 (15-52) Sex Male, n (%)405 (88.6)86 (87.7)319 (88.8) Female, n (%)52 (11.4)12 (12.3)40 (11.2) Management Dali CDC, n (%)103 (22.5)20 (20.4)83 (23.1) Compulsory detoxification, n (%)259 (56.7)58 (59.2)201 (56.0) Labor camp, n (%)95 (20.8)20 (20.4)75 (20.9) Risk group Intravenous injection, n (%)452 (98.9)97 (98.9)355 (98.9) Sex, n (%)5 (1.1)1 (1.1)4 (1.1)

10 98/457(21.4) anti-HCV+ HIV+ subjects were HCV RNA- HCV prevalence, spontaneous clearance and genotype distribution 481/528 (91.1%) HCV infected among HIV+ 457/528 (86.6) anti-HCV+ among HIV +

11 VariableCleared HCV (%)Chronic HCV (%)OR (95%CI)P sex Male 86 (21.2)319 (78.8) 1.00 0.7607 Female 12 (23.1)40 (76.9) 1.113 (0.559-2.213) Age groups (y) <=3032 (26.2)90 (73.8)1.00 0.2591 0.0853 31-3956 (21.1)210 (78.9)0.750 (0.455-1.236) >=4010 (15.2)56 (84.8)0.502 (0.229-1.101) HAART No 92 (21.0)346 (79.0) 1.000.2188 Yes 6 (33.3)12 (66.7) 1.880 (0.687-5.145) HBV coinfection uninfected31 (17.7)144 (82.3)1.00 Resolved43 (18.7)187 (81.3)1.068 (0.641-1.779)0.8001 Chronic HBV24 (46.2)28 (53.8)3.982 (2.039-7.775)<0.0001 CD4 counts (cells/ul) <40039 (16.5)197 (83.5)1.00 >40053 (25.6)154 (74.4)1.738 (1.093-2.765)0.0195 ALT(u/ml) <=4059 (28.2)150 (71.8)1.00 40-8024 (13.7)151 (86.3)0.404 (0.239-0.683)0.0007 >=8015 (20.5)58 (79.5)0.658 (0.346-1.250)0.2010 TB coinfection Uninfected, n(%)92 (21.3)340 (78.7) 1.00 Infected, n(%)6 (24.0)19 (76.0) 1.167 (0.453-3.006)0.7490 Univariate analysis of correlates of HCV clearance

12 Washington D.C., USA, 22-27 July 2012www.aids2012.org Multivariate logistic regression model for HCV clearance VariableOR (95% CI)P CD4 counts (cells/ul) <4001.00 >4001.881 (1.147-3.086)0.0123 HAART No1.00 yes2.865 (0.942-8.715)0.0636 HBV coinfection uninfected1.00 Resolved HBV0.977 (0.564-1.692)0.9327 Chronic HBV4.965 (2.419-10.192)<0.0001 ALT(u/ml) <=401.00 40-800.370 (0.210-0.653)0.0006 >=800.451 (0.218-0.935)0.0321 The model was adjusted for age and gender

13 Washington D.C., USA, 22-27 July 2012www.aids2012.org Clinical features of 231 HIV-infected patients with detectable HCV genotypes HCV genotype VariablesTotal136P CD4 counts (cells/μl) <40013132(24.4)76(58.0)23(17.6) >4009312(12.9)63(67.7)18(19.4)0.1001 HBV coinfection Uninfected9922(22.2)65(65.7)12(12.1) Resolved HBV10615(14.2)70(66.0)21(19.8) Chronic HBV268(30.8) 10(38.5)0.0029 ALT (u/ml) <=408116(19.8)48(59.3)17(21.0) 40-8010720(18.7)69(64.5)18(16.8) >=80439(20.9)26(60.5)8(18.6)0.9470 HCV viral load <50000015931(19.5)104(65.4)24(15.1) >5000007214(19.4)39(54.2)19(26.4)0.1103

14 HCV genotype VariablesTotal3Non-3P HBV coinfection Uninfected9965(65.7)34(34.3) Chronic HBV268(30.8)18(69.2)0.0013 Total13P HBV coinfection Uninfected8722(25.3)65(74.7) Chronic HBV168(50.0) 0.0455 Total6Non-6P HBV coinfection Uninfected9912(12.1)87(87.9) Chronic HBV2610(38.5)16(61.5)0.0017 Total6Non-6P HCV viral load <50000015924(15.1)135(84.9) >5000007219(26.4)53(73.6)0.0411 The appearance rate of different HCV genotype among HBV uninfected / chronic infected subjects

15 Washington D.C., USA, 22-27 July 2012www.aids2012.org Conclusions The prevalence of HCV was 91.1% among HIV-infected IDUs, the spontaneous clearance rate was 21.4%. Our results suggested that the reserved host immune function (high CD4+T counts) and HBV co-infection (chronic HBV) could improve HCV clearance in HIV-infected IDUs whereas the damage in liver (high level of ALT) was associated with the non-clearance of HCV. We demonstrated that the clearance of different HCV genotypes might be facilitated by different factors. HBV chronic infection seemed to facilitate HCV genotype 3 clearance but not genotype 1 and 6. Further cohort studies are needed to determine the influences of HCV genotypes and HBV co-infection on the HCV spontaneous clearance.

16 Washington D.C., USA, 22-27 July 2012www.aids2012.org We thank all the patients and investigators! Chao Qiu, Fudan University Xueshan Xia, Kunming University of Science and Technology Jing Wang, Fudan University Haiyan Zhang, Dali CDC Yongheng Wang, Dali CDC Guomei Sun, Fudan University Xiaoyan Zhang, Fudan University Jianqing Xu, Fudan University This work was supported by 973 program (2012CB519005) and National Grand Program on Key Infectious Disease Control (2012ZX10001-006). Acknowledgements

17 Washington D.C., USA, 22-27 July 2012www.aids2012.org

18 Washington D.C., USA, 22-27 July 2012www.aids2012.org HCV genotype 1 infection stratified by CD4 counts HCV genotype VariablesTotal1Non-1P CD4 counts (cells/μl) <40013132(24.4)99(75.6) >4009312(12.9)81(87.1)0.0324

Download ppt "Washington D.C., USA, 22-27 July 2012www.aids2012.org HCV genotype and HBV co-infection associate with HCV clearance in HIV- positive subjects Yuan Dong,"

Similar presentations

Saotharlann Náisiúnta Tagartha Viris UCD UCD National Virus Reference Laboratory Dr. Jeff Connell Assistant Director National Virus Reference Laboratory.

Saotharlann Náisiúnta Tagartha Viris UCD UCD National Virus Reference Laboratory Dr. Jeff Connell Assistant Director National Virus Reference Laboratory.
Using longitudinal, population-based HIV surveillance to measure the real-world impacts of ART scale-up in KwaZulu- Natal, South Africa Frank Tanser Presentation.

Using longitudinal, population-based HIV surveillance to measure the real-world impacts of ART scale-up in KwaZulu- Natal, South Africa Frank Tanser Presentation.
HLA-B57 does not fully explain the ability of HIV controllers to clear HCV infection Alice K. Asher 1, RN, MS; Glenn-Milo Santos 1, MPH; Jennifer Evans,

HLA-B57 does not fully explain the ability of HIV controllers to clear HCV infection Alice K. Asher 1, RN, MS; Glenn-Milo Santos 1, MPH; Jennifer Evans,
PEPFAR Hepatitis B co-infection and Response to Antiretroviral Therapy among HIV-infected Patients in Tanzania Oral abstract # MOAB0101 C. Hawkins, B.

PEPFAR Hepatitis B co-infection and Response to Antiretroviral Therapy among HIV-infected Patients in Tanzania Oral abstract # MOAB0101 C. Hawkins, B.
Prevalence of and Progression to Abnormal Non-Invasive Markers of Liver Disease (APRI and FIB-4) among US HIV-infected Youth Kapogiannis B, Leister E,

Prevalence of and Progression to Abnormal Non-Invasive Markers of Liver Disease (APRI and FIB-4) among US HIV-infected Youth Kapogiannis B, Leister E,
The Progression of Liver Fibrosis is Associated with the Severity of the HIV Disease in HIV-HCV Co-infected Female Patients Mohammad K. Mohammad 1, Babu.

The Progression of Liver Fibrosis is Associated with the Severity of the HIV Disease in HIV-HCV Co-infected Female Patients Mohammad K. Mohammad 1, Babu.
Institutes: Ukrainian Medical and Dental Academy, Regional HIV/AIDS Prevention and Control Center, Poltava Ukraine Toll-like receptor 4 polymorphism influence.

Institutes: Ukrainian Medical and Dental Academy, Regional HIV/AIDS Prevention and Control Center, Poltava Ukraine Toll-like receptor 4 polymorphism influence.
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.

1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
Hepatitis B: Epidemiology

Hepatitis B: Epidemiology
Hepatitis web study H EPATITIS W EB S TUDY H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School.

Hepatitis web study H EPATITIS W EB S TUDY H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School.
Results Table 1: Factors associated with advanced liver fibrosis in univariable analysis among 216 chronic HCV patients Background There is a clinical.

Results Table 1: Factors associated with advanced liver fibrosis in univariable analysis among 216 chronic HCV patients Background There is a clinical.
Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.

Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.
Module 3: HCV prevalence and course of HCV infection.

Module 3: HCV prevalence and course of HCV infection.
Seroprevalence of HBV and HCV among Children in the Kilimanjaro Region, Tanzania Florida J. Muro, Suzanne P. Fiorillo, Christopher Odhiambo, Coleen K.

Seroprevalence of HBV and HCV among Children in the Kilimanjaro Region, Tanzania Florida J. Muro, Suzanne P. Fiorillo, Christopher Odhiambo, Coleen K.
Patient Empowerment Impacts Medication Adherence among HIV-Positive Patients in the Veteran’s Health Administration Tan Pham 1,2,3, Kristin Mattocks 1,2,

Patient Empowerment Impacts Medication Adherence among HIV-Positive Patients in the Veteran’s Health Administration Tan Pham 1,2,3, Kristin Mattocks 1,2,
Epidemiology and Prevention of Viral Hepatitis A to E: Hepatitis D (Delta) Virus Division of Viral Hepatitis.

Epidemiology and Prevention of Viral Hepatitis A to E: Hepatitis D (Delta) Virus Division of Viral Hepatitis.
M ALNUTRITION. M ALNUTRITION AMONG IDU S : B ASIC FACTS Drug users are at increased risk of malnutrition regardless of whether or not they are infected.

M ALNUTRITION. M ALNUTRITION AMONG IDU S : B ASIC FACTS Drug users are at increased risk of malnutrition regardless of whether or not they are infected.
World Hepatitis Day 2013, 29 th July Establishing a framework for better data collection and surveillance of Hepatitis in South Africa N. Prabdial-Sing.

World Hepatitis Day 2013, 29 th July Establishing a framework for better data collection and surveillance of Hepatitis in South Africa N. Prabdial-Sing.
Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.
The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.

The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.

Similar presentations

Ads by Google